Paloma Partners’s Novo Nordisk NVO Stock Holding History

Paloma Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-317,200	Closed	-$5.69M	–	2151
2016 Q4	$5.69M	Buy	+317,200	New	+$5.75M	0.06%	220

Other funds holding NVO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Paloma Partners's NVO Position: Q2 2022 in Review

Paloma Partners sold out of Novo Nordisk (NVO) in Q2 2022, closing a stake of 3,838 shares — an estimated $213K sold.

Paloma Partners first reported a position in NVO in Q3 2015 and held it in 8 quarters. The position peaked at $2.47M in Q4 2016. 932 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

Paloma Partners reported no remaining Novo Nordisk position as of Q2 2022 after selling out during the quarter.
Paloma Partners sold 3,838 Novo Nordisk shares in Q2 2022, an estimated $213K.
Paloma Partners first reported a position in Novo Nordisk in Q3 2015 and held it in 8 quarters.
Paloma Partners's Novo Nordisk position peaked at $2.47M in Q4 2016.
932 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on Paloma Partners's 13F filing for Q2 2022, filed 15 Aug 2022.